Benefit of a flash dose of corticosteroids in digestive surgical oncology: a multicenter, randomized, double blind, placebo-controlled trial (CORTIFRENCH).
Fiche publication
Date publication
août 2022
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AYAV Ahmet, Dr FOURNEL Isabelle, Pr ORTEGA DEBALLON Pablo, Dr ORRY David, Dr LAKKIS Zaher
Tous les auteurs :
Magnin J, Fournel I, Doussot A, Régimbeau JM, Zerbib P, Piessen G, Beyer-Berjot L, Deguelte S, Lakkis Z, Schwarz L, Orry D, Ayav A, Muscari F, Mauvais F, Passot G, Trelles N, Venara A, Benoist S, Messager M, Fuks D, Borraccino B, Trésallet C, Valverde A, Souche FR, Herrero A, Gaujoux S, Lefevre J, Bourredjem A, Cransac A, Ortega-Deballon P
Lien Pubmed
Résumé
The modulation of perioperative inflammation seems crucial to improve postoperative morbidity and cancer-related outcomes in patients undergoing oncological surgery. Data from the literature suggest that perioperative corticosteroids decrease inflammatory markers and might be associated with fewer complications in esophageal, liver, pancreatic and colorectal surgery. Their benefit on cancer-related outcomes has not been assessed.
Mots clés
Digestive surgical oncology, Perioperative corticosteroids, Postoperative morbidity, Randomized placebo-controlled trial, cancer-related outcomes
Référence
BMC Cancer. 2022 08 23;22(1):913